| pubmed-article:18254812 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18254812 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:18254812 | lifeskim:mentions | umls-concept:C0006050 | lld:lifeskim |
| pubmed-article:18254812 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:18254812 | lifeskim:mentions | umls-concept:C0600210 | lld:lifeskim |
| pubmed-article:18254812 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:18254812 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:18254812 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18254812 | pubmed:dateCreated | 2008-2-7 | lld:pubmed |
| pubmed-article:18254812 | pubmed:abstractText | Different formulations of botulinum toxin type A (BoNTA) are not identical and may behave differently in clinical practice. The reportedly lower incidence of adverse effects with one formulation (from Allergan, Ltd.) relative to another (from Ipsen, Ltd.) may be due to differences in the degree of migration of the neurotoxin-protein complex from its injection site. A double-blind, randomized, within-subject pilot study was performed to compare the migration characteristics of each formulation. | lld:pubmed |
| pubmed-article:18254812 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18254812 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18254812 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18254812 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18254812 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18254812 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18254812 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18254812 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18254812 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18254812 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:18254812 | pubmed:issn | 1473-2165 | lld:pubmed |
| pubmed-article:18254812 | pubmed:author | pubmed-author:JudodihardjoH... | lld:pubmed |
| pubmed-article:18254812 | pubmed:author | pubmed-author:CliffSandeep... | lld:pubmed |
| pubmed-article:18254812 | pubmed:author | pubmed-author:EltringhamEli... | lld:pubmed |
| pubmed-article:18254812 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18254812 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:18254812 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18254812 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18254812 | pubmed:pagination | 50-4 | lld:pubmed |
| pubmed-article:18254812 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:meshHeading | pubmed-meshheading:18254812... | lld:pubmed |
| pubmed-article:18254812 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18254812 | pubmed:articleTitle | Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. | lld:pubmed |
| pubmed-article:18254812 | pubmed:affiliation | Epsom and St. Helier University NHS Trust, and Surrey and Sussex NHS Trust, UK. sandeep_cliff@hotmail.com | lld:pubmed |
| pubmed-article:18254812 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18254812 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18254812 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18254812 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18254812 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18254812 | lld:pubmed |
